UQ, UniQuest and Pfizer’s CTI Biotherapeutic Partnership

Call for Translational Funding Applications due 13 October 2017

PRE-PROPOSAL APPLICATION

A1.DESCRIPTIVE RESEARCH TITLE(max. 20 words)

Subject of CTI Research Project

A2.EXECUTIVE SUMMARY

Provide a BRIEF statement summarizing the following:
  • Overall goal and impact of the mechanism
  • Desired characteristics
  • Patient stratification and evidence of proof of mechanism (PoM)

A3.NAME OF LEAD APPLICANT (Full details of UQ researcher to lead this application)

Surname / Given Name / Position / Faculty/Institute / Email
1

If the Lead Applicant is not a UQ clinical researcher, it is recommended that a clinical investigator from UQ be involved in the program to bring insight and expertise from the beginning of the project on clinical trial design and proof of mechanism studies.

A4.NAME OF OTHER APPLICANTS(Full details of other UQ researchers in this application, if any)

Surname / Given Name / Position / Faculty/Institute / Email
2
3

A5.SCIENTIFIC RATIONALE AND BACKGROUND(maximum 500 words or 1 page with graphics)

This section should contain:
  • A brief description of the target/pathway, the disease mechanism(s) and link to human disease. What is/are the unmet medical need(s) this target/pathway could address? Is this pathway targetable with a biotherapeutic?
  • The novelty/differentiation of the target or approach relevant to disease mechanism (if there are other treatments available, please describe why this is different – greater efficacy/safety etc)
  • Key evidence available to support the hypothesis above (i.e., human genetic, human tissue, pre-clinical proof-of-mechanism/concept models).

A6.PROPOSED BIOTHERAPEUTIC DRUG CANDIDATE (maximum 200 words)

Please describe any available potential biotherapeutic molecule(s) the UQ team has generated against the target and its mechanism of action. If available, please describe the characteristics of said molecule (affinity, humanisation, PK etc). (Please be sure to communicate within limits of any Intellectual Property constraints). If unavailable, please indicate the characteristics of the preferred biotherapeutic agent.

A7.CLINICAL SIGNIFICANCE(maximum 250 words)

This section should contain:
  • What is the clinical significance of the potential biotherapeutic?

A8.CONCEPT FOR FIRST BIOLOGICAL READOUT IN CLINIC (PROOF OF MECHANISM) (maximum 200 words)

Brief description of potential therapeutic indications expected to be impacted by this mechanism. Describe the first potential clinical study(ies) to demonstrate proof of mechanism Including:
1)Patient stratification/selection for the study (i.e. molecular signature, SNP, genetic deficiency etc)
2)Clinical study endpoints that would allow for testing mechanism in patients
3)Will this allow for clinical differentiation from other therapies?

A9.RESEARCH PLAN and REAGENTS (maximum 500 words)

Provide a brief description of research plan to be carried out (objectives, specific aims) leading to demonstration of proof of mechanism. Please list the available reagents and assays to support research plan. Alternatively, please describe reagents and assays that may need to be developed, and any gaps in the plan (and how Pfizer scientists may contribute, i.e. complete mechanistic studies in vitro, develop cellular assays, discover biomarkers, etc.)

A.10. PRINCIPAL INVESTIGATOR and RESEARCH TEAMCAPABILITIES (maximum 300 words)

Please provide a brief bio-sketch of the Lead Applicant and key publications along with details of relevant capabilities of the other investigator(s) in your team, their labs and collaborators.

Contacts available for more information or advice on your application

/ Professor Darrell Crawford
MD FRACP
Head of the School of Clinical Medicine, UQ

Member of the UQ/UniQuest-Pfizer CTI Joint Steering Committee
/ Professor John Prins
MBBS PhD FRACP FAHMS
Director, Mater Research Institute-UQ

Member of the UQ/UniQuest-Pfizer CTI Joint Steering Committee
/ Dr Mark Ashton
Executive Director, IP Commercialisation, UniQuest

Member of the UQ/UniQuest-Pfizer CTI Joint Steering Committee
/ Dr Craig Belcher
Senior Director, Commercial Engagement – Health, UniQuest
Office on UQ St Lucia campus

Coordinator of the UQ/UniQuest-Pfizer CTI Joint Steering Committee
/ Dr Ben Phillis
Director, Commercial Engagement – Health, UniQuest
Office at UQ on Herston site

/ Dr Maher Khaled
Director, Commercial Engagement – Health, UniQuest
Office at UQ on PA Hospital site

/ Dr Stephen Earl
Director, Commercial Engagement – Health, UniQuest
Office on UQ St Lucia campus

/ Dr George Adamson
Director, Commercial Engagement – Health, UniQuest
Office on UQ St Lucia campus

Completed Pre-Proposal applications must be emailed Friday 13th October 2017

Page 1 of 4